Project Grant R01CA292775
Award Date
6/23/25
Completion Date
5/31/30
Dollars Obligated
$779K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $400,000 to Oncotab, Inc. to develop an optimized targeted radiotherapy for pancreatic ductal adenocarcinoma (PDAC). The project aims to use a tumor-specific antibody, HTAB004, and a tandem single-chain variable fragment (scFv) to target PDAC tumors and deliver alpha and beta particle-emitting radioisotopes. Through a structured design of experiments, the project will evaluate how the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $1,130,538.00 to the University of Louisville to develop a novel targeted therapeutic strategy against metastatic pancreatic ductal adenocarcinoma (PDAC). The key focus is on investigating the cancer-specific expression of the Tn antigen and its role in PDAC progression, metastasis, and survival. The research aims to determine the mechanisms by which the Tn antigen enhances PDAC, identify...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $571,350.00 in funding to the Sanford Burnham Prebys Medical Discovery Institute (SBP) in La Jolla, California. The award supports research aimed at developing metabolic interventions to halt the progression of pancreatic cancer. SBP, an independent non-profit biomedical research organization, will leverage advanced technologies and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) is supporting research conducted by the University of Texas MD Anderson Cancer Center to investigate the role of sulfatide metabolism in the development and progression of pancreatic cancer precursor lesions. The $616,495 grant, awarded on March 1, 2025, has a 5-year project period ending on February 28, 2030. The key objectives of this research are to: 1) define the biological functions...
This federal Project Grant award of $642,755.00 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research by The Institute For Cancer Research (ICR) to investigate the role of the protein Anoctamin 6 (ANO6) in disrupting lipid transfer from cancer-associated fibroblasts to pancreatic cancer cells. The key objectives are to: 1) Delineate how ANO6 activity is regulated in the interface between cancer cells and fibroblasts; 2) Determine how...
The National Cancer Institute (NCI) awarded a 5-year, $654,197 Project Grant (CFDA 93.396 - Cancer Biology Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on pancreatic ductal adenocarcinoma (PDAC). The key objectives are to: Define the molecular subtypes of PDAC that respond to standard-of-care chemotherapies like FOLFIRINOX and gemcitabine + Abraxane. Elucidate how different stromal subtypes within patient-derived...
The National Cancer Institute (NCI) awarded a $268,345 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Sanford Burnham Prebys Medical Discovery Institute (SBP) to develop a novel immunotherapy for pancreatic cancer based on blockade of the PSGL-1/VISTA axis. The goal is to investigate how disrupting this pathway can enhance T cell responses and overcome resistance to current immune checkpoint blockade treatments. The project will interrogate the role of the...
The National Cancer Institute (NCI), part of the National Institutes of Health, awarded a $269,280 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Translational Genomics Research Institute (TGen) to conduct research on targeting cellular senescence in pancreatic cancer. The key goals of this 2-year project (02/01/2025 - 01/31/2027) are to determine the biological effects of a senescent cell-targeted antibody, SIWA318, and evaluate its ability to improve the efficacy of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,688,087 to the Sanford Burnham Prebys Medical Discovery Institute (SBP) to investigate macropinocytosis inhibition as a strategy to sensitize pancreatic ductal adenocarcinoma (PDAC) tumors to glutamine mimetic treatments. The key objectives are to: (1) examine the role of macropinocytosis as a metabolic adaptation to the glutamine mimetic 6-diazo-5-oxo-L-norleucine (DON) in PDAC, and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $145,000.00 in funding to the University of Oklahoma Health Sciences Center to investigate the role of the JMJD4 enzyme in pancreatic cancer. The research aims to determine how JMJD4 affects the growth and invasiveness of pancreatic tumor cells, as well as its potential mechanisms of action through modulating transcription factors NRF2 and HIF-2A. This work is expected to advance...